Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Innate Pharma SA

< Previous 1 2 3 4 5 Next >
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Outcome of Innate Pharma’s 2025 Annual General Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma announces conference call and webcast for Q1 2025 business update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces €15M Investment by Sanofi
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Transformative Strategy to Accelerate Growth
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
From Innate Pharma SA
Via Business Wire
Tickers IPHA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.